ADT	Androgen deprivation therapy
AR	Androgen receptor
ARAmw	Androgen receptor activity Mann–Whitney score
AREs	androgen response elements
ARSis	Androgen receptor signaling inhibitors
AR-Vs	Androgen receptor splice variants
ASO	Antisense oligonucleotides
BAT	Bipolar androgen therapy
BET	Bromodomain and extra-terminal
CRPC	Castration-resistant prostate cancer
DBD	DNA-binding domain
DHT	Dihydrotestosterone
DSBs	Double-strand breaks
EA	Adverse events
EZH2	Histone lysine-N-methyltransferase
GR	Glucocorticoid receptor
HDACs	Histone deacetylases
HDACIs	HDAC inhibitors
IGF-1	Insulin-like growth factor-1
IL-6	Interleukin-6
IR	Ionizing radiation
LBD	Ligand-binding domain
LHRH	Luteinizing hormone-releasing hormone
MAOAIs	Monoamine oxidase A inhibitors
mCRPC	Metastatic castration-resistant prostate cancer
NE	Neuroendocrine
NEPC	Neuroendocrine prostate cancer
NTD	Terminal transactivation domain
NK	Natural killer
OR	Objective response
ORR	Objective response rate
PARP	Poly ADP-ribose polymerase
PCa	Prostate cancer
PCSCs	Prostate cancer stem-like cells
PFS	Progression-free survival
PSA50	≥50% PSA reduction
Retinoblastoma	Rb
TICs	Tumor-initiating cells